CL2024001022A1 - Moléculas pequeñas para el tratamiento del cáncer - Google Patents
Moléculas pequeñas para el tratamiento del cáncerInfo
- Publication number
- CL2024001022A1 CL2024001022A1 CL2024001022A CL2024001022A CL2024001022A1 CL 2024001022 A1 CL2024001022 A1 CL 2024001022A1 CL 2024001022 A CL2024001022 A CL 2024001022A CL 2024001022 A CL2024001022 A CL 2024001022A CL 2024001022 A1 CL2024001022 A1 CL 2024001022A1
- Authority
- CL
- Chile
- Prior art keywords
- small molecules
- cancer treatment
- kras
- relates
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000003384 small molecules Chemical class 0.000 title 1
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a nuevos compuestos descritos en el presente documento, el método de preparación de la misma, su composición farmacéutica y el método para el uso de los mismos. En particular, la invención se refiere a compuestos de fórmula (A) o sus sales farmacéuticamente aceptables de los mismos como inhibidores de la proteína KRAS y útil en el tratamiento, prevención y / o mejora de las enfermedades o trastornos asociados con KRAS especialmente el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141046053 | 2021-10-08 | ||
| US202263308727P | 2022-02-10 | 2022-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001022A1 true CL2024001022A1 (es) | 2024-09-27 |
Family
ID=83995446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001022A CL2024001022A1 (es) | 2021-10-08 | 2024-04-05 | Moléculas pequeñas para el tratamiento del cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240300942A1 (es) |
| EP (1) | EP4412710A1 (es) |
| JP (1) | JP2024538851A (es) |
| KR (1) | KR20240073982A (es) |
| CN (1) | CN119604502A (es) |
| AU (1) | AU2022361766A1 (es) |
| CA (1) | CA3233985A1 (es) |
| CL (1) | CL2024001022A1 (es) |
| CO (1) | CO2024005925A2 (es) |
| IL (1) | IL312009A (es) |
| MX (1) | MX2024004327A (es) |
| WO (1) | WO2023057985A1 (es) |
| ZA (1) | ZA202403388B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE295362T1 (de) * | 2001-01-02 | 2005-05-15 | Hoffmann La Roche | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten |
| US7312330B2 (en) * | 2003-12-24 | 2007-12-25 | Renovis, Inc. | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| TW200530235A (en) * | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| EP1725556A1 (en) * | 2004-03-09 | 2006-11-29 | Merck & Co., Inc. | Hiv integrase inhibitors |
| CA2814703A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Hiv integrase inhibitors |
| CN102827170A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| WO2013134518A1 (en) * | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| CN110382482A (zh) * | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| WO2020239077A1 (zh) * | 2019-05-29 | 2020-12-03 | 上海翰森生物医药科技有限公司 | 含氮杂环类衍生物调节剂、其制备方法和应用 |
| CN116194456B (zh) * | 2020-04-30 | 2025-08-29 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
-
2022
- 2022-10-07 JP JP2024545072A patent/JP2024538851A/ja active Pending
- 2022-10-07 MX MX2024004327A patent/MX2024004327A/es unknown
- 2022-10-07 KR KR1020247015343A patent/KR20240073982A/ko active Pending
- 2022-10-07 US US18/260,928 patent/US20240300942A1/en active Pending
- 2022-10-07 CN CN202280075115.XA patent/CN119604502A/zh active Pending
- 2022-10-07 AU AU2022361766A patent/AU2022361766A1/en active Pending
- 2022-10-07 WO PCT/IB2022/059630 patent/WO2023057985A1/en not_active Ceased
- 2022-10-07 CA CA3233985A patent/CA3233985A1/en active Pending
- 2022-10-07 IL IL312009A patent/IL312009A/en unknown
- 2022-10-07 EP EP22793849.5A patent/EP4412710A1/en active Pending
-
2024
- 2024-04-05 CL CL2024001022A patent/CL2024001022A1/es unknown
- 2024-04-30 ZA ZA2024/03388A patent/ZA202403388B/en unknown
- 2024-05-07 CO CONC2024/0005925A patent/CO2024005925A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240073982A (ko) | 2024-05-27 |
| IL312009A (en) | 2024-06-01 |
| JP2024538851A (ja) | 2024-10-23 |
| WO2023057985A1 (en) | 2023-04-13 |
| ZA202403388B (en) | 2025-01-29 |
| US20240300942A1 (en) | 2024-09-12 |
| EP4412710A1 (en) | 2024-08-14 |
| AU2022361766A1 (en) | 2024-05-16 |
| CN119604502A (zh) | 2025-03-11 |
| CO2024005925A2 (es) | 2024-07-18 |
| MX2024004327A (es) | 2024-08-28 |
| CA3233985A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CL2024001964A1 (es) | Compuestos para la inhibición de nlrp3 y usos de estos | |
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| CO2026004964A2 (es) | Moduladores de kras | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| MX2019004685A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer. | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CR20210213A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| DOP2026000079A (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| AR131001A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| AR131413A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| AR131414A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| ECSP24007193A (es) | Compuestos pirimidínicos para usar como inhibidores de map4k1 | |
| CL2023002064A1 (es) | Derivados de ácido urólico sintético y métodos de uso de estos | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| MX2022001023A (es) | Compuestos de aminotiolester y usos de los mismos. |